New Phase 3 data show HYMPAVZI dramatically cuts bleeding episodes in hemophilia A and B patients with inhibitors
Pfizer unveiled very encouraging topline results from its Phase 3 BASIS clinical trial (NCT03938792). The study examined once‑weekly, under‑skin injections of HYMPAVZI (marstacimab) in adolescents and adults (12 years+) living with hemophilia A or B complicated by inhibitors an antibody that can neutralize traditional factor replacement therapy.